Frontiers in Immunology (Oct 2021)
COVID-19 Is a Multi-Organ Aggressor: Epigenetic and Clinical Marks
- Mankgopo Magdeline Kgatle,
- Mankgopo Magdeline Kgatle,
- Ismaheel Opeyemi Lawal,
- Ismaheel Opeyemi Lawal,
- Ismaheel Opeyemi Lawal,
- Gabriel Mashabela,
- Tebatso Moshoeu Gillian Boshomane,
- Tebatso Moshoeu Gillian Boshomane,
- Tebatso Moshoeu Gillian Boshomane,
- Tebatso Moshoeu Gillian Boshomane,
- Palesa Caroline Koatale,
- Palesa Caroline Koatale,
- Phetole Walter Mahasha,
- Honest Ndlovu,
- Mariza Vorster,
- Hosana Gomes Rodrigues,
- Jan Rijn Zeevaart,
- Jan Rijn Zeevaart,
- Jan Rijn Zeevaart,
- Siamon Gordon,
- Siamon Gordon,
- Pedro Moura-Alves,
- Mike Machaba Sathekge,
- Mike Machaba Sathekge,
- Mike Machaba Sathekge
Affiliations
- Mankgopo Magdeline Kgatle
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Mankgopo Magdeline Kgatle
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Ismaheel Opeyemi Lawal
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Ismaheel Opeyemi Lawal
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Ismaheel Opeyemi Lawal
- Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, South Africa
- Gabriel Mashabela
- SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DSI/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- Tebatso Moshoeu Gillian Boshomane
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Tebatso Moshoeu Gillian Boshomane
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Tebatso Moshoeu Gillian Boshomane
- Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, South Africa
- Tebatso Moshoeu Gillian Boshomane
- Nuclear and Oncology Division, AXIM Medical (Pty), Midrand
- Palesa Caroline Koatale
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Palesa Caroline Koatale
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Phetole Walter Mahasha
- Precision Medicine and SAMRC Genomic Centre, Grants, Innovation, and Product Development (GIPD) Unit, South African Medical Research Council, Pretoria, South Africa
- Honest Ndlovu
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Mariza Vorster
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Hosana Gomes Rodrigues
- Laboratory of Nutrients and Tissue Repair, School of Applied Sciences, University of Campinas, Campinas, Brazil
- Jan Rijn Zeevaart
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Jan Rijn Zeevaart
- South African Nuclear Energy Corporation, Radiochemistry and NuMeRI PreClinical Imaging Facility, Mahikeng, South Africa
- Jan Rijn Zeevaart
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan
- Siamon Gordon
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan City, Taiwan
- Siamon Gordon
- 0Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom
- Pedro Moura-Alves
- 1Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
- Mike Machaba Sathekge
- Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa
- Mike Machaba Sathekge
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa
- Mike Machaba Sathekge
- SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DSI/NRF Centre of Excellence for Biomedical TB Research, Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
- DOI
- https://doi.org/10.3389/fimmu.2021.752380
- Journal volume & issue
-
Vol. 12
Abstract
The progression of coronavirus disease 2019 (COVID-19), resulting from a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, may be influenced by both genetic and environmental factors. Several viruses hijack the host genome machinery for their own advantage and survival, and similar phenomena might occur upon SARS-CoV-2 infection. Severe cases of COVID-19 may be driven by metabolic and epigenetic driven mechanisms, including DNA methylation and histone/chromatin alterations. These epigenetic phenomena may respond to enhanced viral replication and mediate persistent long-term infection and clinical phenotypes associated with severe COVID-19 cases and fatalities. Understanding the epigenetic events involved, and their clinical significance, may provide novel insights valuable for the therapeutic control and management of the COVID-19 pandemic. This review highlights different epigenetic marks potentially associated with COVID-19 development, clinical manifestation, and progression.
Keywords
